Deutsche Bank Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $90
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Deutsche Bank analyst David Hoang maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raises the price target from $56 to $90.
Deutsche Bank analyst David Hoang maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raises the price target from $56 to $90.